Multiple Myeloma | Clinical

CARTITUDE-1 Study Demonstrates Promising Response Rates in Relapsed/Refractory Myeloma

January 22, 2021

Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.

Rationale Taken From Trial Data for Using Daratumumab in Multiple Myeloma

January 19, 2021

During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Alex Mejia-Garcia, MD, medical oncologist, Cleveland Clinic, discussed the use of daratumumab as treatment of multiple myeloma. The discussion was based on the case scenario of a 51-year-old patient.

Safety Findings Appear Encouraging for REGN5458 in Relapsed/Refractory Myeloma

January 14, 2021

Deepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to Novel BCMA-Targeted Agent in Multiple Myeloma

January 13, 2021

The FDA has granted an Orphan Drug Designation to the B-cell maturation antigen BCMA-targeting tri-specific T cell activating recombinant protein construct, HPN217 for the treatment of patients with multiple myeloma.

Treatment Landscape of Multiple Myeloma Expands With Supportive QOL Data

January 11, 2021

In an interview with Targeted Oncology, Nina Shah, MD, discussed the findings from the KarMMA study supporting the use of idecabtagene vicleucel as treatment of patients with multiple myeloma.

Use of Daratumumab Suggested for Transplant-Ineligible Myeloma

January 01, 2021

During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in Myeloma

December 28, 2020

Mehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.